CERS (Cerus Corp)
Insider Trading Activity
Every open-market purchase and sale reported by CERS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Chrystal Jensen | Chief Legal Officer | Sell | — | — |
| 2026-07-20 | Vivek K Jayaraman | Chief Executive Officer | Sell | — | — |
| 2026-07-02 | Chrystal Jensen | Chief Legal Officer | MIXED | — | — |
| 2026-07-02 | Vivek K Jayaraman | Chief Operating Officer | MIXED | — | — |
| 2026-07-02 | William Mariner Greenman | President and CEO | MIXED | — | — |
| 2026-07-02 | Kevin Dennis Green | Chief Financial Officer | MIXED | — | — |
| 2026-06-11 | ERIC BJERKHOLT | Director | Sell | — | — |
| 2026-06-02 | ERIC BJERKHOLT | Director | A | — | — |
| 2026-06-02 | Frank Witney | Director | A | — | — |
| 2026-06-02 | Ann Lucena | Director | A | — | — |
| 2026-06-02 | Dean A. Gregory | Director | A | — | — |
| 2026-06-02 | Hua Shan | Director | A | — | — |
| 2026-06-02 | JAMI K NACHTSHEIM | Director | A | — | — |
| 2026-06-02 | Vivek K Jayaraman | Chief Operating Officer | Sell | — | — |
| 2026-05-05 | Vivek K Jayaraman | Chief Operating Officer | Sell | — | — |
| 2026-04-03 | Kevin Dennis Green | Chief Financial Officer | A | — | — |
| 2026-04-03 | Chrystal Jensen | Chief Legal Officer | A | — | — |
| 2026-03-16 | Richard J Benjamin | Chief Medical Officer | Sell | — | — |
| 2026-03-16 | William Mariner Greenman | President and CEO | Sell | — | — |
| 2026-03-16 | Kevin Dennis Green | Chief Financial Officer | Sell | — | — |
| 2026-03-16 | Vivek K Jayaraman | Chief Operating Officer | Sell | — | — |
| 2026-03-16 | Chrystal Jensen | Chief Legal Officer | Sell | — | — |
| 2026-03-10 | Richard J Benjamin | Chief Medical Officer | MIXED | — | — |
| 2026-03-09 | Vivek K Jayaraman | Chief Operating Officer | MIXED | — | — |
| 2026-03-09 | Kevin Dennis Green | Chief Financial Officer | MIXED | — | — |
| 2026-03-09 | William Mariner Greenman | President and CEO | MIXED | — | — |
| 2026-03-09 | Chrystal Jensen | Chief Legal Officer | MIXED | — | — |
| 2026-03-09 | Richard J Benjamin | Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | Vivek K Jayaraman | Chief Operating Officer | A | — | — |
| 2026-03-04 | Kevin Dennis Green | Chief Financial Officer | A | — | — |
| 2026-03-04 | Richard J Benjamin | Chief Medical Officer | A | — | — |
| 2026-03-04 | Chrystal Jensen | Chief Legal Officer | A | — | — |
| 2026-03-04 | William Mariner Greenman | President and CEO | A | — | — |
| 2025-11-26 | Chrystal Jensen | Chief Legal Officer | Sell | — | — |
| 2025-08-25 | Dean A. Gregory | Director | Buy | — | — |
| 2025-06-04 | Hua Shan | Director | A | — | — |
| 2025-06-04 | Daniel N Swisher JR | Director | A | — | — |
| 2025-06-04 | TIMOTHY L. MOORE | Director | A | — | — |
| 2025-06-04 | JAMI K NACHTSHEIM | Director | A | — | — |
| 2025-06-04 | ERIC BJERKHOLT | Director | A | — | — |
| 2025-06-04 | Ann Lucena | Director | A | — | — |
| 2025-06-04 | Frank Witney | Director | A | — | — |
| 2025-03-17 | Richard J Benjamin | Chief Medical Officer | Sell | — | — |
| 2025-03-17 | Chrystal Jensen | Chief Legal Officer | Sell | — | — |
| 2025-03-17 | Vivek K Jayaraman | Chief Operating Officer | Sell | — | — |
| 2025-03-17 | William Mariner Greenman | President and CEO | Sell | — | — |
| 2025-03-17 | Kevin Dennis Green | Chief Financial Officer | Sell | — | — |
| 2025-03-10 | Chrystal Jensen | Chief Legal Officer | MIXED | — | — |
| 2025-03-10 | Vivek K Jayaraman | Chief Operating Officer | MIXED | — | — |
| 2025-03-10 | Richard J Benjamin | Chief Medical Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 5,154,955 | — |
| — | Chief Scientific Officer | 2,354,100 | — |
| — | Chief Executive Officer | 2,232,211 | — |
| — | Chief Financial Officer | 1,095,864 | — |
| — | Chief Legal Officer | 936,657 | — |
| — | Chief Medical Officer | 777,361 | — |
| — | SVP Reg. & Quality | 511,242 | — |
| — | Director | 340,059 | — |
| — | Director | 268,362 | — |
| — | Director | 261,679 | — |
| — | Director | 232,284 | — |
| — | Director | 213,993 | — |
| — | Director | 207,045 | — |
| — | Director | 205,073 | — |
| — | Director | 192,386 | — |
| — | Executive Officer and Director | 189,457 | — |
| — | Director | 182,384 | — |
| — | Director | 163,420 | — |
| — | Chief Financial Officer | 156,825 | — |
| — | Director | 146,725 | — |
| — | Vice President, R & D | 43,836 | — |
| — | Vice President, Legal Affairs | 42,846 | — |
| — | Director | 18,921 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CERS quote page; the site-wide leaderboard is on the insider transactions hub.